Abstract:Microglial activation is intimately associated with Alzheimer's disease (AD), however its exact role in AD is unknown. Positron emission tomography (PET) imaging of translocator protein 18 kDa (TSPO), a biomarker of microglial activation, could enhance our understanding of the in vivo role of microglia in AD, and might serve as a marker of AD progression and treatment response. We aim to evaluate a TSPO-specific radioligand [18 F]PBR06 for visualizing alterations in TSPO and microglial activation in a transgenic mouse model of AD, Thy1-hAPP Lond/Swe (APP L/S). APP L/S mice (n=5) and wild-type (wt) littermates (n=5) underwent [18 F]PBR06-PET/computed tomography (CT) imaging at either 9–10 months or 15–16 months of age. 7T magnetic resonance (MR) images were fused with PET/CT data (attenuation corrected) to quantify [18 F]PBR06 uptake in hippocampus (H) and cortex (Ctx). Brain sections from mice were analyzed via digital autoradiography (ARG), and subsequently stained to evaluate levels of microglia (CD68), plaques (ThioS), and TSPO. Brain [18 F]PBR06 signal was significantly higher in 15–16 month APP L/S mice compared to wts (1.36 ± 0.06 vs. 1.06 ± 0.10 %ID/g, p<0.05); however, no significant difference was found between 9–10 month old mice (p = 0.49). Analysis of specific brain regions known to contain increasing levels of microglial activation in AD revealed an even greater difference in [18 F]PBR06 signal (normalized to muscle) between 15–16 month old APP L/S and wts (Ctx: 1.52 ± 0.09 vs. 0.87 ± 0.14, p<0.005; H: 1.59 ± 0.13 vs. 0.92 ± 0.14, p<0.005). Similarly, ARG images showed significantly higher [18 F]PBR06 signal in 15–16 month APP L/S mice compared to wts (Ctx: 1.32 ± 0.04 vs. 1.00 ± 0.10 %ID/g, p<0.005; H: 1.36 ± 0.06 vs. 1.07 ± 0.01 %ID/g, p<0.05). Unexpectedly, we observed a significantly higher signal in the choroid plexus of APP L/S mice in ARG images (1.99 ± 0.05 vs. 1.53 ± 0.02, p<0.005). This is the first demonstration of TSPO-related molecular alterations in the choroid plexus of an AD mouse model. Lastly, we showed that ARG and PET results correlated well with immunostaining - i.e., increased [18 F]PBR06 uptake in brain regions containing elevated CD68, ThioS, and TSPO staining in APP L/S compared to wts. [18 F]PBR06 -PET/MR imaging shows great potential as a tool for investigating the in vivo role of microglia and TSPO in the progression and treatment of AD. Results from [18F]PBR06-PET/MRI mouse brain imaging and ex vivo autoradiography (ARG). A) Coronal PET/CT/MRI images of [18F]PBR06 accumulation in APPL/S versus wild-type (wt) mice at 15–16 months of age; B) Ex vivo ARG of coronal APPL/S and wt mouse brain sections shown on the same scale. Nissl staining of same sections are shown below for anatomical correlation. Ctx = cortex and H = hippocampus. Arrows point to choroid plexus.

Multiple Inflammatory Profiles of Microglia and Altered Neuroimages in APP/PS1 Transgenic AD Mice.

Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.

Genome-wide Analysis of Mirna Signature in the APPswe/PS1ΔE9 Mouse Model of Alzheimer's Disease.

Preliminary study on early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice using multimodal magnetic resonance imaging

Study of Regional Metabolites by Quantitative Proton MR Spectroscopy in APP/PS1 Double Transgenic Alzheimer Disease Mice

Analysis of Serum Β-Amyloid Peptides, Α2-Macroglobulin, Complement Factor H, and Clusterin Levels in APP/PS1 Transgenic Mice During Progression of Alzheimer's Disease.

Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology.

iTRAQ-based Proteomic Analysis of APPSw,Ind Mice Provides Insights into the Early Changes in Alzheimer's Disease.

Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer's disease

Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease

Morphological and Molecular Alterations of Reactive Astrocytes Without Proliferation in Cerebral Cortex of an APP/PS1 Transgenic Mouse Model and Alzheimer's Patients

Early amyloid‐induced changes in microglia gene expression in male APP/PS1 mice

Analysis the alteration of systemic inflammation in old and young APP/PS1 mouse

Differences in Immune-Related Genes Underlie Temporal and Regional Pathological Progression in 3xTg-AD Mice

Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology

O2–11–05: Imaging Microglial Activation in a Mouse Model of Alzheimer's Disease Using PET/MRI and Ex Vivo Autoradiography

Increased Hippocampal Neurogenesis in the Progressive Stage of Alzheimer's Disease Phenotype in an APP/PS1 Double Transgenic Mouse Model.

Microvascular ultrastructural changes precede cognitive impairment in the murine APPswe/PS1dE9 model of Alzheimer's disease

In Vivo [18F]SMBT‐1 Imaging of Reactive Astrocytes in Mouse Models of Alzheimer’s Disease ‐ Temporospatial Relationship with Amyloid, Tau and Microgliosis

Proteomic profiles of the early mitochondrial changes in APP/PS1 and ApoE4 transgenic mice models of Alzheimer disease.

Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease